Magnesium Sulphate 25% Solution for Injection

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Active ingredient:

Magnesium sulphate heptahydrate

Available from:

Chanelle Pharmaceuticals Manufacturing Limited

ATC code:

QA12CC02

INN (International Name):

Magnesium sulphate heptahydrate

Dosage:

25 percent weight/volume

Pharmaceutical form:

Solution for injection

Prescription type:

LR: Licensed Retailer as defined in national legislation

Therapeutic group:

Cattle

Therapeutic area:

magnesium sulfate

Therapeutic indications:

Vitamins and minerals

Authorization status:

Authorised

Authorization date:

1991-10-01

Summary of Product characteristics

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Magnesium Sulphate 25% Solution for Injection.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Active Substance:
Magnesium Sulphate Heptahydrate
25.0 % w/v
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Solution for injection.
A clear colourless sterile aqueous solution.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cattle.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
It is indicated in the treatment of hypomagnesaemia and
hypomagnesaemic tetany.
4.3 CONTRAINDICATIONS
Do not use in animals with known hypersensitivity to the active
ingredient.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Administer with care particularly for very slow intravenous use.
Intravenous injection should be given slowly and
stopped at once if untoward symptoms occur.
As intravenous administration of this product could cause death, this
route should only be used by a veterinary surgeon.
Use aseptic technique.
Bring contents to body temperature in cold
weather prior to administration.
Massage the subcutaneous site of injection during administration and
for a short period
after.
SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE
VETERINARY MEDICINAL PRODUCT TO ANIMALS
None.
4.6 ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS)
I
R
I
S
H
M
E
D
I
C
I
N
E
S
B
O
A
R
D
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_0_
_6_
_/_
_0_
_9_
_/_
_2_
_0_
_1_
_1_
_C_
_R_
_N_
_ _
_7_
_0_
_0_
_1_
_2_
_8_